CIPLA.NS Stock Today: 2-Year Low, 20% YTD Slide — April 03 Update

Cipla share price slipped to a fresh 2-year low today, extending a near 20% YTD decline as US headwinds persist. CIPLA.NS traded around ₹1,192.40 with an intraday low of ₹1,165.70. Management cut FY26 EBITDA margin guidance to about 21% after a 26% YoY drop in US sales on gRevlimid erosion and a Lanreotide supply disruption. With Q4 results due on May 13, investors in India are weighing near-term downside against planned respiratory and peptide launches later this year. We break down levels, drivers, and what to watch next.

Cipla hits a 2-year low: what changed

The Cipla share price hovered near ₹1,192.40, down 0.29% today, after touching ₹1,165.70. The stock is down 20.55% YTD and well below the 52-week high of ₹1,673. Volume spiked to about 31.29 lakh versus a 18.73 lakh average, signaling distribution. The stock also trades under its 50-DMA at ₹1,308.90 and 200-DMA at ₹1,468.28, keeping sentiment weak.

Management cited a 26% YoY fall in US sales, driven by gRevlimid erosion and a temporary Lanreotide supply disruption, which pressured margins. Guidance now pegs FY26 EBITDA margin near 21%. The Cipla share price reflects this near-term pressure. The Q4 results on May 13 are key for clarity on the speed of US recovery and the cadence of upcoming launches.

News reports highlight the 2026 underperformance and the fresh multi-year low as traders reassess US exposure. See live price snapshots and market color on Economic Times and a broader take on the 2026 slide in Business Standard. Both reinforce the focus on US normalization and margin delivery.

Fundamentals at a glance

At today’s Cipla share price, the stock trades at 21.22x TTM EPS of ₹56.19 and 2.92x book. Dividend yield stands near 1.34% with a payout ratio of 28.43%. Profitability remains solid with ROE at 14.68% and net margin at 16.11%. For context, price-to-sales is 3.41x, reflecting quality but limited near-term growth visibility.

Leverage is low with a 0.014 debt-to-equity ratio and interest coverage of 79.46, implying ample buffer. Liquidity is healthy with a current ratio of 3.96, while net debt to EBITDA is negative, signaling net cash. Cash per share is about ₹103.24. These strengths help cushion earnings volatility as US sales stabilize and new launches ramp.

Working capital needs are elevated: DSO is 89 days, inventory sits at 174 days, and the cash conversion cycle is 178 days. R&D spend is 10.45% of revenue, supporting respiratory and peptide pipelines. SG&A is 22.96% of revenue. The Cipla share price may re-rate if execution lifts growth while holding this margin and efficiency mix steady.

Technical picture: trend, momentum, and levels

Most signals remain negative. RSI is 23.99, indicating oversold conditions, but ADX at 45 points to a strong prevailing downtrend. MACD is below the signal line, confirming bearish momentum. Price trades beneath the 50-DMA at ₹1,308.90 and 200-DMA at ₹1,468.28. For the Cipla share price, sustained closes back above the 50-DMA would improve tone.

ATR of 29.91 suggests wider daily swings. Bollinger Bands show the lower band near ₹1,178, close to today’s lows, while the middle band is around ₹1,278. Keltner’s lower channel sits near ₹1,205. The Cipla share price could attempt short bounces from these zones, but confirmation requires higher highs and strength above ₹1,278 to ₹1,300.

What to watch before Q4 results

Key swing factors include recovery in Lanreotide supply, stabilization in US base business, and the timing of planned respiratory and peptide launches later in 2026. India business trends and pricing discipline also matter. Any sign that demand and supply improve sooner could help the Cipla share price rebuild support into the second half of FY26.

Cipla reports Q4 on May 13. We will track the US sales decline rate, margin progress toward the ~21% FY26 target, and management commentary on launch timelines, pricing, and inventory. Cash flow and capex runway will be under the lens. This setup keeps the Cipla share price sensitive to both delivery and guidance tone.

If launches land on time and US normalization takes hold, margins could recover into H2 FY26, aiding sentiment. If not, downside risk persists. Watch support at ₹1,150 to ₹1,180 and resistance near ₹1,278 to ₹1,300. Today’s volume of about 31.29 lakh versus 18.73 lakh average suggests distribution that traders will monitor.

Final Thoughts

The Cipla share price is testing patience after a 2-year low and a 20% YTD slide, driven by US pressures from gRevlimid erosion and a temporary Lanreotide supply disruption. Fundamentals, however, show low leverage, solid liquidity, and steady profitability, which cushion near-term shocks. Technicals are oversold but the trend stays down until price reclaims the ₹1,278 to ₹1,300 zone. Into the May 13 Q4 print, investors should focus on three items: progress toward the ~21% EBITDA margin for FY26, clarity on US stabilization, and the launch timeline for respiratory and peptide assets. Delivery on these items could reset expectations. Until then, expect elevated volatility and respect key support and resistance levels.

FAQs

Why did the Cipla share price fall to a 2-year low?

Weakness in the US business is the main driver. Management flagged a 26% YoY drop in US sales due to gRevlimid erosion and a temporary Lanreotide supply disruption. Margin guidance for FY26 is now about 21%, which weighed on sentiment and pushed the Cipla share price to new lows.

What are the key technical levels for Cipla stock today?

Near-term support sits around ₹1,150 to ₹1,180, close to the lower Bollinger Band near ₹1,178. The middle band is about ₹1,278. Resistance is around ₹1,300, near the 50-DMA at ₹1,308.90. A sustained move above this band would help improve the Cipla share price tone.

When is Cipla reporting earnings and what should investors watch?

Cipla reports Q4 on May 13. Focus on the pace of US sales stabilization, progress toward the ~21% FY26 EBITDA margin, and updates on respiratory and peptide launch timelines. Cash flow and capex guidance will also influence the Cipla share price reaction after the print.

Is the Cipla share price attractive after the recent fall?

Valuation has eased to about 21x TTM earnings with solid ROE and low leverage, but growth visibility in the US is still uncertain. For many, confirmation may require evidence of supply normalization and launch execution. The Cipla share price could re-rate if these catalysts land on schedule.

How does the Lanreotide supply disruption affect Cipla’s outlook?

It hurt near-term US sales and margins, contributing to the FY26 EBITDA margin guidance of roughly 21%. If supply normalizes soon, revenue and profitability can improve in the second half of FY26. The Cipla share price should respond to updates on timing and the scale of recovery.

Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.